...
首页> 外文期刊>Molecular Imaging and Biology >NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy of 3′-Deoxy-3′-[18F]fluorothymidine (FLT) as a Marker of Proliferation in Patients with Recurrent Gliomas: Preliminary Efficacy Studies
【24h】

NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy of 3′-Deoxy-3′-[18F]fluorothymidine (FLT) as a Marker of Proliferation in Patients with Recurrent Gliomas: Preliminary Efficacy Studies

机译:NCI赞助的评估3'-脱氧-3'-[18 F]氟胸苷(FLT)作为复发性胶质瘤患者增殖指标的安全性和初步疗效的初步疗效研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) is being developed for imaging cellular proliferation. The goals were to explore the capacity of FLT-positron emission tomography (PET) to distinguish between recurrence and radionecrosis in gliomas and compare the results to those obtained with 2-fluoro-2-deoxy-d-glucose (FDG).
机译:3'-Deoxy-3'-[18 F]氟胸苷([18 F] FLT)正在开发中,用于细胞增殖成像。目的是探索FLT正电子发射断层扫描(PET)的能力,以区分神经胶质瘤的复发和放射性坏死,并将结果与​​使用2-氟-2-脱氧-d-葡萄糖(FDG)获得的结果进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号